Publications by authors named "Parasar Pal"

Claim this Profile
F
First-in-human safety, tolerability, and pharmacokinetic results of DFV890, an oral low-molecular-weight NLRP3 inhibitor.
Ewa Gatlik, Beata Mehes, Emilie Voltz, Ulrike Sommer, Elaine Tritto, Parasar Pal

Clin Transl Sci· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects.
Anne Gardin, Mike Ufer, Eric Legangneux, Gianluca Rossato, Yi Jin, Parasar Pal

Clin Pharmacokinet· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects.
Uwe Schuehly, Surya Ayalasomayajula, Jeppe Buchbjerg, Parasar Pal, Georg Golor

Eur J Clin Pharmacol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic Interaction Between Fingolimod and Carbamazepine in Healthy Subjects.
Olivier J David, Rhett Behrje, Parasar Pal, Hisanori Hara, Christian D Lates

Clin Pharmacol Drug Dev· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide.
Surya Ayalasomayajula, Uwe Schuehly, Parasar Pal, Fabian Chen, Wei Zhou

Br J Clin Pharmacol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.
Surya Ayalasomayajula, Thomas Langenickel, Parasar Pal, Sreedevi Boggarapu, Gangadhar Sunkara

Clin Pharmacokinet· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and Hypertension.
Stefan Engeli, Rudi Stinkens, Tim Heise, Marcus May, Gijs H Goossens, Parasar Pal

Hypertension· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.
Surya Ayalasomayajula, Thomas Langenickel, Parasar Pal, Sreedevi Boggarapu, Gangadhar Sunkara

Clin Pharmacokinet· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of sacubitril/valsartan (LCZ696) in patients with mild and moderate hepatic impairment
.
Kenneth M Kulmatycki, Thomas Langenickel, Wai Hong Ng, Parasar Pal, Wei Zhou

Int J Clin Pharmacol Ther· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension.
Stefan Engeli, Marcus May, Juerg Nussberger, A H Jan Danser, William P Dole, Parasar Pal

J Am Soc Hypertens· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects.
Mizuki Akahori, Surya Ayalasomayajula, Thomas Langenickel, Parasar Pal, Wei Zhou

Eur J Drug Metab Pharmacokinet· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Drug-Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects.
Surya Ayalasomayajula, Wei Pan, Yi Han, Fan Yang, Thomas Langenickel, Parasar Pal

Eur J Drug Metab Pharmacokinet· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects.
Yi Han, Surya Ayalasomayajula, Wei Pan, Fan Yang, Yaozong Yuan, Parasar Pal

Eur J Drug Metab Pharmacokinet· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension.
Tzung-Dau Wang, Ru-San Tan, Hae-Young Lee, Sang-Hyun Ihm, Moo-Yong Rhee, Parasar Pal

Hypertension· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of food on the oral bioavailability of the angiotensin receptor - neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects
.
Surya Ayalasomayajula, Thomas H Langenickel, Priya Chandra, Edward D Wolfson, Diego Albrecht, Parasar Pal

Int J Clin Pharmacol Ther· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor.
Surya P Ayalasomayajula, Thomas H Langenickel, Pierre Jordaan, Wei Zhou, Priyamvada Chandra, Parasar Pal

Eur J Clin Pharmacol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
Zhanna Kobalava, Yulia Kotovskaya, Oleg Averkov, Elena Pavlikova, Valentine Moiseev, Parasar Pal

Cardiovasc Ther· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization.
Thomas H Langenickel, Pierre Jordaan, Jesika Petruck, Kiran Kode, Parasar Pal

Eur J Clin Pharmacol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects.
Thomas H Langenickel, Chiaki Tsubouchi, Surya Ayalasomayajula, Parasar Pal, Marie-Anne Valentin

Br J Clin Pharmacol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects.
Lu Gan, Xuemin Jiang, Anisha Mendonza, Therese Swan, Christine Reynolds, Parasar Pal

Clin Pharmacol Drug Dev· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol.
Hsiu-Ling Hsiao, Thomas Heiko Langenickel, Michael Greeley, John Roberts, Wei Zhou, Parasar Pal

Clin Pharmacol Drug Dev· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of food effect on the oral bioavailability of pradigastat, a diacylglycerol acyltransferase 1 inhibitor.
Surya P Ayalasomayajula, Charles D Meyers, Jing Yu, Mark Kagan, Ralph Matott, Parasar Pal

Biopharm Drug Dispos· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Renal Impairment on the Pharmacokinetics of Pradigastat, a Novel Diacylglycerol Acyltransferase1 (DGAT1) Inhibitor.
Sachiko Mita, Dan Meyers, Parasar Pal, TsuHan Lin, Tapan Majumdar

Clin Pharmacokinet· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Hepatic Impairment on the Pharmacokinetics of Pradigastat, a Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor.
Masaru Hirano, Dan Meyers, GangaRaju Golla, Parasar Pal, Pascale Pinot

Clin Pharmacokinet· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glycopyrronium does not affect QT interval in healthy subjects: a randomized, three- period, cross-over, placebo- and positive-controlled study.
Anton Drollmann, Romain Sechaud, Parasar Pal, Hisanori Hara, Susan Uziel-Fusi

Int J Clin Pharmacol Ther· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis